ArticleNeurobiology of disease2025
Identification of presenilin mutations that have sufficient gamma-secretase proteolytic activity to mediate Notch signaling but disrupt organelle and neuronal health.
Article in Neurobiology of disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis.Neurotoxicity research · 2026Article
- ZL006 Treatment Reduces Inflammation, Oxidative Stress, and Brain AβInternational journal of molecular sciences · 2026Article
- From mechanistic modeling to AI-driven design: computational strategies for targeting the γ-secretase complex.Briefings in bioinformatics · 2026Review
- Tunable tau expression in C. elegans neurons reveals that early-AD tau phosphorylation selectively impacts behavior and mitochondrial quality control.Neurobiology of disease · 2026Article
- A C. elegans model of familial Alzheimer's disease shows age-dependent synaptic degeneration independent of amyloid β-peptide.Neurobiology of disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mutations that cause familial Alzheimer's disease (AD) are predominantly found in the presenilin (PSEN) encoding genes PSEN1 and PSEN2. While the association of PSEN mutations with familial AD have been known for over 20 years, the mechanism underlying the impact these mutations have on disease is not fully understood. PSENs are phylogenetically conserved proteins that are found in diverse multicellular organisms ranging from plants to humans. PSENs form the proteolytic core of gamma-secretase that is required for cleaving type I transmembrane proteins, such as Notch receptors and the amyloid precursor protein. Importantly, familial AD-associated PSEN mutations are broadly distributed and do not clearly define a specific PSEN function essential for neuronal fitness. Here, using C. elegans as a model organism to study the in vivo functions of PSENs, we confirm that C. elegans PSEN plays a pivotal role in gamma-secretase proteolytic activity as well as maintaining neuronal and organelle health. Notably, we demonstrate that these two functions can be genetically uncoupled. Our research identifies several conserved familial AD-like missense mutations in the endogenous sel-12 gene, which encodes C. elegans PSEN. These mutations preserve sufficient gamma-secretase proteolytic activity to mediate Notch signaling but abolish PSEN's role in supporting neuronal and organelle health. Furthermore, we provide evidence that these familial AD-like missense mutations disrupt mitochondrial calcium regulation, ultimately leading to neuronal dysfunction. These results indicate that C. elegans PSEN plays at least two independent roles: one that mediates gamma-secretase proteolytic activity and another that mediates organelle and neuronal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.